Boehringer Ingelheim Press Releases

MorphoSys Signs Manufacturing Agreement with Boehringer Ingelheim

Porcine Circovirus remains in the spotlight of European researchers

Pfēnex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement for the use of Pfēnex Expression Technology™

Elan and Boehringer Ingelheim Announce Development and Manufacturing Agreement for Elan’s Antibody-Based Therapeutics Pipeline

PRAZAXA® (dabigatran etexilate) approved in Japan for stroke prevention in atrial fibrillation

Boehringer Ingelheim to Purchase Amgen’s Fremont (USA) Facility

EPIC trial with pimobendan* examines delay of congestive heart failure in dogs

Boehringer Ingelheim and Eli Lilly and Company Announce Strategic Alliance to Bring New Diabetes Treatments to Patients Worldwide

Boehringer Ingelheim and Orexo report progress in their pain and inflammatory diseases collaboration

Boehringer Ingelheim and Orexo report progress in their pain and inflammatory diseases collaboration

New subgroup analysis of the LUX-Lung 1 trial suggests benefit from afatinib* in lung cancer patients likely to have EGFR mutations

Trial indicates that BIBF1120 may preserve lung function in patients with idiopathic Pulmonary Fibrosis (IPF)

Boehringer Ingelheim steps up to the challenge in support of World Diabetes Day

Collaboration of Boehringer Ingelheim and VTU Technology in Technology and Marketing benefits customers with broader services

Boehringer Ingelheim RCV and Fresenius Kabi successfully coupled HES to a therapeutic protein in an industrial scale applying Fresenius Kabi’s HESylation® Technology 

Dabigatran etexilate demonstrates substantial clinical benefits in atrial fibrillation patients with prior stroke or transient ischaemic attack

Boehringer Ingelheim's oral hepatitis C protease inhibitor and polymerase inhibitor combination shows rapid viral response without use of pegylated interferon